CDP870

DRUG4 trials

Sponsors

UCB Pharma, Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc

Conditions

Active Rheumatoid ArthritisArthritis, RheumatoidRheumatoid Arthritis

Phase 3

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

CompletedNCT00544154

UCB PharmaArthritis, Rheumatoid

Start: 2002-10-31End: 2004-01-31Updated: 2013-09-04

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

CompletedNCT00548834

UCB PharmaRheumatoid Arthritis

Start: 2003-06-30End: 2004-07-31Target: 220Updated: 2013-09-04

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

CompletedNCT00791921

Otsuka Pharmaceutical Co., Ltd.Rheumatoid Arthritis

Start: 2008-11-30End: 2010-01-31Updated: 2012-08-07

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

CompletedNCT02586246

Astellas Pharma IncActive Rheumatoid Arthritis

Start: 2011-01-31End: 2013-05-31Updated: 2015-11-16

Related Papers

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

2017-03-2810 citations

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.

2013-11-0140 citations

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

2012-02-1653 citations

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

2008-11-17227 citations